US Patent 6,415,797 Patent Landscape and Claim-Validity Analysis (US)

US 6,415,797 claims methods for treating infections by a “human herpesvirus” by transiently raising patient core temperature (hyperthermia) to a defined range for defined durations, then returning core temperature to normal (optionally one or multiple cycles), with viral-load reduction measured at a specified post-treatment timepoint (one month in independent Claim 1; three months in independent Claim 45). The claims also layer in specific monitoring (viral load determination before and/or after), specific delivery hardware (extracorporeal heated blood circuit), and optional combination therapy with a wide drug list including antivirals and chemotherapeutics (notably doxorubicin and liposomal doxorubicin), plus broad infectious-context recitals (acute vs latent infection; co-infection with other pathogens).

What do the independent claims actually cover?

Claim 1: “One-month” efficacy hyperthermia

Core elements:

Condition: “patient infected with a human herpesvirus” (broad genus selection in dependent claims).
Intervention: raise core temperature, then return to normal at least once.
Parameters: core temperature raised to a range; duration sufficient to reduce viral load.
Efficacy metric: viral load reduction by ≥30% measured one month after core temperature has been raised and returned to normal.
Measurement: viral load determined at least once after temperature has been returned to normal (and Claim 8 adds “at least once before”).

Independent Claim 1 is a “treating method” defined by post-treatment viral-load reduction rather than a mechanism. This makes infringement and validity hinge on clinical protocol choices that affect (i) actual temperature exposure and (ii) viral-load readout timing and assay.

Claim 45: “Three-month” efficacy hyperthermia (parallel family)

Independent Claim 45 mirrors Claim 1, but changes:

Efficacy metric timing: viral load reduction by ≥30% at three months after temperature has been raised and returned to normal.

The family structure matters: if an accused protocol lands closer to one-month readouts, Claim 1 is the sharper hook; if it lands on longer durability measured at three months, Claim 45 is targeted.

What are the key claim construction pressure points (for enforcement and validity)?

1) “Core temperature” and the control window

The independent claims require raising and returning core temperature and define the efficacy as a function of that exposure. Dependent claims narrow the range:

Claim 5: 38 to 44°C
Claim 6: 2 minutes to 16 hours
Claim 7: 0.5 to 3 hours

Enforcement will likely focus on whether a defendant’s protocol:

uses a measurable and documented “core temperature” approach (as opposed to skin temperature or localized hyperthermia),
stays within the defined temperature-duration constraints, and
defines “duration sufficient” in a way consistent with the claimed range/duration subsets.

2) Timing of viral-load measurement

The independent claims are defined by a post-treatment timepoint (one month vs three months). Dependent claims also require assay-type “sensitivity level” thresholds:

Claim 13 (branched DNA signal amplification test): reduced below sensitivity one month after
Claim 14 (RT-PCR): reduced below sensitivity one month after
Claim 57 (branched DNA): three months
Claim 58 (RT-PCR): three months

This means an accused regimen that shows reduction but uses a different measurement timepoint can avoid at least part of the claim scope. Conversely, measuring at the claimed timepoint can increase infringement exposure if viral-load reduction meets or exceeds the claimed thresholds.

3) “At least one time” cycles

Claim 2: one cycle
Claim 3: two or more cycles
Claim 45/46/47: parallel for the three-month claim set

This matters because hyperthermia regimens often use single-session or repeated-session protocols. The claim family makes repeated exposure a literal target.

4) Delivery hardware: extracorporeal heated blood circuit

Claim 4/48: raising core temperature by circulating the patient’s blood through an extracorporeal circuit and heating blood within the circuit.

This is a narrower apparatus-defined method element. Many hyperthermia approaches exist (surface heating, endovascular catheters, blankets, microwave/RF localized heating, etc.). The claims are not limited to any specific hyperthermia generator beyond the extracorporeal heated-blood circuit in the relevant dependent claims, but those dependent claims provide enforcement leverage against extracorporeal systems.

5) Viral load reduction thresholds (30% to 95%)

Claims create a ladder:

Claim 1/45: ≥30%
Claim 9/53: ≥50%
Claim 10/54: ≥75%
Claim 11/55: ≥90%
Claim 12/56: ≥95%

And then “below sensitivity” variants (Claims 13-14, 57-58). This granularity means an accused protocol that achieves, say, 40% reduction one month out would satisfy the ≥30% branch but not the ≥50% or higher branches.

6) Assay choice as claim substance

The “branched DNA signal amplification” and “reverse transcriptase-polymerase chain reaction” sensitivity-level limitations incorporate a testing modality. This creates potential non-infringement arguments when trials use other assay platforms or if sensitivity calculations do not map to the claimed thresholds.

7) Broad drug add-ons with mechanistic mismatch risks

Claim 15 and onward add pharmaceutical treatment for the herpesvirus, with extensive enumerations:

Claim 19: interferons, protease inhibitors, cytokines, chemotherapeutic agents
Claim 20: long list of specific drugs including ribavirin, lamivudine, aciclovir, ganciclovir, foscarnet, valacyclovir, zidovudine, protease inhibitors (ritonavir, indinavir, etc.), doxorubicin
Claim 21: interferon, ribavirin, lamivudine, or doxorubicin
Claim 22: alpha interferon
Claim 23: doxorubicin
Claim 24: liposomal doxorubicin

This breadth increases infringement surface for combination therapies, but it also increases novelty/obviousness scrutiny if combination timing and administration are not unique. The claims specify administration timing as dependent limits:

Claim 16: before raising temperature
Claim 17: while temperature is raised
Claim 18: after temperature is returned to normal

8) “Human herpesvirus” scope is broad via list

Dependent Claims 35-43 and 79-87 define:

HHV-8 (Kaposi sarcoma-associated herpesvirus)
EBV
HCMV
VZV
HSV-1 and HSV-2
HHV-6 and HHV-7

Claim 44 and Claim 88 narrow to a specific clinical scenario:

HHV-8 patient receiving doxorubicin with progressive Kaposi’s sarcoma prior to treating.

That narrower scenario can act as a factual anchor for validity arguments if prior art did not address hyperthermia as an adjunct in this exact context.

Where do the claims sit relative to the prior art buckets (critical landscape)?

Hyperthermia as an antiviral strategy (general category)

Core temperature elevation to treat infections is a known medical concept across oncology and some infectious disease contexts. The novelty in US 6,415,797, as pleaded by the claims themselves, appears to concentrate in:

targeting “human herpesviruses” specifically,
specifying a core-temperature range (38-44°C) and duration windows,
requiring viral-load reduction by defined percentages and assay/timing criteria.

A validity attack for such method claims typically proceeds in two tracks: 1) Obviousness: general hyperthermia and viral reduction were already known, and parameter ranges were routine optimization. 2) Anticipation: a prior clinical method already disclosed these parameters and outcomes.

The claim set’s dependence on viral-load reduction at one month and three months means anticipatory prior art must include those clinical readouts at those timepoints, which is less common in early hyperthermia publications.

Delivery architecture (extracorporeal heated blood)

Extracorporeal thermal management is also a known engineering space. The dependent claim tying extracorporeal heated blood circuits to herpesvirus viral-load reduction can be vulnerable if:

the thermal delivery method was already used for systemic hyperthermia in clinical contexts, and
the herpesvirus application was a routine therapeutic adaptation.

But it can also be stronger if prior art was limited to cancer or non-herpes viral infections with different endpoints.

Combination therapy breadth

The drug lists and “before/while/after” administration timing create a large combination claim space. This can be attacked as:

overbroad relative to the described rationale for any specific drug,
merely additive (hyperthermia + standard antiviral/chemotherapy),
obvious to combine once hyperthermia became a known approach.

Conversely, combination claims can survive if prior art does not teach that timing relative to thermal exposure yields viral-load reduction at the claimed intervals.

Claim chart style breakdown: independent claim elements likely to be litigated

Element (from Claim 1 / Claim 45)	What it forces in practice	Most likely infringement evidence	Most likely design-around
“Human herpesvirus” patient infection	Identify the virus classification used	Baseline diagnosis and viral species	Treat only non-listed viruses or argue virus classification
Raise core temperature then return to normal	Show controlled thermal exposure and normalization	Core temperature logs, protocol records	Use different thermal targets (e.g., localized heating)
Temperature range (dependent: 38 to 44°C)	Match exact temperature window if asserted	Device records, nursing charts	Keep temperature outside claimed range
Duration (dependent: 2 min to 16 hrs; or 0.5 to 3 hrs)	Match time exposure	Temperature-time curves	Use longer/shorter durations
≥30% viral-load reduction	Achieve effect magnitude	Viral-load assays with computed reduction	Achieve less than threshold or alternate treatment
Measurement timing: one month vs three months	Use readout window	Trial endpoints, assay schedules	Use different assessment timeline
Viral-load determined at least once after	Take post-treatment measurement	Laboratory reports	Skip or postpone post-treatment viral-load readout
Optional extracorporeal heated blood (dependent)	Use heated blood circuit	Device/therapy protocol documentation	Use alternate hyperthermia modalities
Optional drug adjunct + timing	Administer specific pharmaceuticals as claimed	Medication administration records	Use different drug class or different timing

How strong are the claims for enforcement (practical lens)?

Strengths:

Multiple independent endpoints (viral-load reduction by threshold) provide measurable criteria.
Temperature windows and durations are explicitly narrowed in dependent claims.
Viral-load assays are specified in dependent claims (branched DNA and RT-PCR), which supports clear measurement.
Combination therapy dependent claims include specific drug identities (doxorubicin, liposomal doxorubicin), which can be commercially tied to known drug regimens.

Weaknesses that reduce practical enforcement:

The “core temperature raised then returned to normal” and specified temperature ranges can be easy to avoid by shifting thermal exposure outside 38-44°C or altering session timing.
The claims tie outcomes to exact post-treatment windows (one month and three months). Many clinical studies record earlier kinetics or different endpoints; shifting endpoint timing can be a design-around.
Dependent assay-sensitivity limitations can be avoidable if other assay platforms are used or if sensitivity levels are defined differently.

How crowded is the patent landscape for this concept?

US 6,415,797 operates in a crowded thematic zone:

hyperthermia in oncology,
systemic temperature control devices (including extracorporeal thermal circuits),
antiviral therapy for herpesviruses,
viral load measurement and clinical trial endpoint design.

Crowding cuts both ways. It increases the odds that aspects of the claims (temperature delivery, herpesvirus viral load monitoring, use of antivirals/interferons) appeared in multiple documents. It also increases the odds that the claims will be narrowed by prior art in validity analysis unless the combination of:

specific core temperature window,
specific duration,
specific viral-load reduction magnitude, and
specific measurement timing is found in a single earlier reference or in a coherent obviousness combination.

The claim set’s dependence on “viral load reduced by X% one month/three months” raises the bar for anticipation because a reference must include both protocol parameters and that specific clinical readout schedule.

Which claim clusters matter most for freedom-to-operate (FTO)?

Cluster A: Temperature protocol without drugs

Primary risk if a competitor protocol uses:

38 to 44°C core temperature,
session durations within 2 minutes to 16 hours (or 0.5 to 3 hours),
measurement of herpesvirus viral load one month or three months post-thermal exposure,
reported reductions meeting ≥30% (and possibly higher thresholds).

Cluster B: Extracorporeal heated blood

Add risk if a competitor uses extracorporeal heated blood to achieve systemic core temperature and claims clinical viral-load reductions at the specified endpoints.

Cluster C: Combination with antivirals or doxorubicin

Risk rises sharply if a competitor:

administers specific drugs listed in the claims (especially doxorubicin/liposomal doxorubicin), and
times administration relative to heating (before, during, after), and
uses claimed viral load endpoints.

Key Takeaways

US 6,415,797 claims are defined by systemic core hyperthermia paired with herpesvirus viral-load reduction measured at one month (Claim 1) or three months (Claim 45), with additional dependent claims specifying temperature range, duration, assay type, and delivery method (extracorporeal heated blood).
The enforcement-critical limitations are the combination of (i) core temperature control, (ii) session duration, and (iii) endpoint timing and magnitude of viral-load reduction.
The patent landscape is crowded around hyperthermia and antiviral treatment, so validity strength will depend on whether prior art already disclosed the same parameter-and-endpoint combination for herpesviruses.
For FTO, the biggest design-around levers are: shifting thermal exposure outside the claimed core temperature/duration windows and changing the viral-load assessment schedule away from the claimed one-month or three-month timepoints.

FAQs

1) What is the independent inventive idea in this patent?

It is transient raising and then normalizing patient core temperature to achieve a clinically measurable reduction in human herpesvirus viral load, quantified at one month (Claim 1) or three months (Claim 45).

2) What temperature and time ranges are explicitly claimed?

Dependent claims specify core temperature 38 to 44°C (Claim 5/49) and duration 2 minutes to 16 hours (Claim 6/50) or 0.5 to 3 hours (Claim 7/51).

3) How do the viral-load endpoints work?

Independent claims require at least ≥30% viral-load reduction, with dependent claims stepping up to ≥50%, ≥75%, ≥90%, and ≥95%, and also including “below sensitivity level” for branched DNA and RT-PCR at either one month or three months.

4) Does the patent require extracorporeal heated blood?

No. Extracorporeal heated blood is a dependent limitation (Claim 4/48). The independent claims focus on core temperature raising and returning to normal with viral-load reduction at the claimed timepoints.

5) Which herpesviruses are covered?

Dependent claims list HHV-8, EBV, HCMV, VZV, HSV-1, HSV-2, HHV-6, and HHV-7.

References

[1] United States Patent 6,415,797. “Method for treating human herpesvirus infection using transient hyperthermia and viral load reduction endpoints.” (Claims as provided in prompt).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	June 04, 1986	6,415,797	2020-07-07
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132		6,415,797	2020-07-07
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	Injection	103132		6,415,797	2020-07-07
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	May 17, 1996	6,415,797	2020-07-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 6,415,797

Summary for Patent: 6,415,797